About this trial
Craniotomy presents true anesthetic challenges, mainly due to the need to optimize cerebral perfusion, facilitate brain relaxation, achieve rapid emergence for neurologic assessment, and minimize perioperative complications.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient acceptance.
Physical status: American Society of Anesthesiologists Physical Status (ASA) 1& II.
Body mass index ≤ 30 kg/m2.
Type of operation: elective craniotomy for brain tumor resection.
Disqualifiers
Patient with hemodynamic instability or anticipated postoperative mechanical ventilation.
Patients with a known history of allergy to the study drugs.
Advanced hepatic, renal, cardiovascular, and neurologic diseases.
Patients with chronic opioid use.
Trial design
Parallel
Treatments tested in this trial
Dexmedetomidine
DrugDexmedetomidine as an adjunct to total intravenous anesthesia.
Fentanyl
DrugFentanyl as an adjunct to total intravenous anesthesia.
Magnesium
DrugMagnesium sulphate as an adjunct to total intravenous anesthesia.
Treatment groups
Trial outcomes
Primary outcomes
The total intraoperative propofol consumption
The total intraoperative propofol consumption (in milligrams).
Secondary outcomes
Intraoperative heart rate
Monitoring the changes in heart rate intraoperative.
Intraoperative mean arterial pressure
Monitoring the changes in mean arterial pressure intraoperative.
Brain relaxation score
Evaluating the brain relaxation right after the dura is opened using a scale from 1 to 4 (1 = perfectly relaxed, 2 = satisfactorily relaxed, 3 = firm brain, 4 = bulging brain).
Additional doses of intraoperative fentanyl.
The total number of patients requiring additional dose of intraoperative fentanyl.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.